Jeffrey Walch
Stock Analyst at Bernstein
(1.77)
# 3,183
Out of 4,382 analysts
8
Total ratings
100%
Success rate
10.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Walch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintained: Hold | $96 | $88.08 | +8.99% | 2 | Jun 4, 2026 | |
| SMMT Summit Therapeutics | Reiterated: Sell | $7.7 | $14.77 | -47.87% | 2 | May 31, 2026 | |
| INCY Incyte | Initiated Coverage: Hold | $99 | $102.38 | -3.30% | 1 | May 21, 2026 | |
| JAZZ Jazz Pharmaceuticals | Initiated Coverage: Hold | $229 | $238.57 | -4.01% | 1 | May 21, 2026 | |
| NBIX Neurocrine Biosciences | Initiated Coverage: Buy | $221 | $163.88 | +34.85% | 1 | May 21, 2026 | |
| RVMD Revolution Medicines | Initiated Coverage: Hold | $151 | $149.23 | +1.19% | 1 | May 21, 2026 |
BioNTech SE
Jun 4, 2026
Maintained: Hold
Price Target: $96
Current: $88.08
Upside: +8.99%
Summit Therapeutics
May 31, 2026
Reiterated: Sell
Price Target: $7.7
Current: $14.77
Upside: -47.87%
Incyte
May 21, 2026
Initiated Coverage: Hold
Price Target: $99
Current: $102.38
Upside: -3.30%
Jazz Pharmaceuticals
May 21, 2026
Initiated Coverage: Hold
Price Target: $229
Current: $238.57
Upside: -4.01%
Neurocrine Biosciences
May 21, 2026
Initiated Coverage: Buy
Price Target: $221
Current: $163.88
Upside: +34.85%
Revolution Medicines
May 21, 2026
Initiated Coverage: Hold
Price Target: $151
Current: $149.23
Upside: +1.19%